As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Poised to Continue Pitching Drugs’ Multi-Faceted Values to Politicians: Director General
March 25, 2019
- 2020 Drug Price Revision Is Focus Issue for FPMAJ in FY2019 Plan
March 25, 2019
- FPMAJ Wants Asian Equivalent of EMA, Chairman Stresses Merit of Blanket Approval
March 20, 2019
- EFPIA Official Prods Japan to Limit CEA Application to Financially Impactful Drugs
March 19, 2019
- Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
- Drug Damage Watchdog Opposes Legislation of Conditional Approval System, Calls for Tougher Rules on Ads
March 13, 2019
- Look at Societal Values of Medicines in Pricing: Japan Pharma Industry Chief
March 12, 2019
- Japan Has High Market Access Barriers, Revised PMP Could Stymie Innovation: US Chamber of Commerce Official
March 7, 2019
- Biotech Execs Raise Alarm over Price Maintenance Criteria, CEA Introduction: BIO Asia Confab
March 6, 2019
- Labor Groups Call for Careful Discussions on Cost Effectiveness Assessment
February 19, 2019
- EFPIA Japan Chief Says CEA Selection Criteria Mar Predictability, 5 Billion Yen Sales Threshold “Too Low”
February 19, 2019
- 2019 Is Year to “Get Things Right”: PhRMA Japan Chairman
February 8, 2019
- Sanofi CEO Becomes Chairman of PhRMA
February 6, 2019
- PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework
February 5, 2019
- JPMA Lays Out Policy Proposal 2019, Advocates Pricing Premium for Drugs Used for Pregnant Women
January 25, 2019
- Think Tank Urges Govt to Look at Drugs with Large Prescription Volumes Too
January 25, 2019
- Regional Formulary Initiatives Underway, Eyes on Cost Control for Branded Drugs with No Gx
January 22, 2019
- Don’t Cause Disruptions in Drug Distribution with October Re-Pricing: Japan Wholesaler Chief
January 15, 2019
- Budget Juggling Dependent on Drug Price Cuts Unacceptable: Tokyo Pharma Chief
January 9, 2019
- Generic Use Rate at 73.2% in July-September: JGA
December 27, 2018
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…